ANNUAL REPORT 2026 27 Relationship between the remuneration policy and Consolidated Entity performance The Board considers that at this time, evaluation of the Consolidated Entity's financial performance using generally accepted measures such as profitability, total shareholder return or benchmarking are not relevant as the Consolidated Entity is in the clinical stage and remains focused on the research and development of its therapeutic candidates. 2026 Short-term employee benefits Postemployment benefits Share-based payments Total Salary & fees1 Bonus Other Superannuation and Options2 $ $ $ $ $ $ Non-executive Directors John Moore3 189,162 - - - 710,007 899,169 Rüdiger Weseloh4 72,769 - - - 355,004 427,773 Marcus Frampton5 79,907 - - - 355,004 434,911 Christopher Cox6 79,907 - - - 355,004 434,911 Ian Dixon7 79,836 - - 9,722 170,838 260,396 Gisela Mautner8 23,205 - - 5,081 2,588 30,874 Executive Directors James Bonnar9 353,574 - 13,086 30,000 289,715 686,375 Total 878,360 - 13,086 44,803 2,238,160 3,174,409 1 Difference in Non-executive directors' salary & fees from financial year 2025 is due to USD/AUD translation differences for their fixed contracts in USD during the financial year. Difference in James Bonnar's salary was due to Remuneration Review announced to ASX 08 October 2025. 2 The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is apportioned from the grant date to the date the options vest. This amount does not represent a cash benefit to the key management personnel. 3 John Moore share-based compensation derived from 3,600,000 share options granted during the period. 1,200,000 options vest on the first, second and third anniversary of the grant date (12 November 2025), subject to continuous employment. 4 Rüdiger Weseloh share-based compensation derived from 1,800,000 share options granted during the period. 600,000 options vest on the first, second and third anniversary of the grant date (12 November 2025), subject to continuous employment. 5 Marcus Frampton share-based compensation derived from 1,800,000 share options granted during the period. 600,000 options vest on the first, second and third anniversary of the grant date (12 November 2025), subject to continuous employment. 6 Christopher Cox share-based compensation derived from 1,800,000 share options granted during the period. 600,000 options vest on the first, second and third anniversary of the grant date (12 November 2025), subject to continuous employment. 7 Ian Dixon share-based compensation derived from 1,200,000 share options granted during the period. 600,000 options vest on the second and third anniversary of the grant date (12 November 2025), subject to continuous employment. 8 Gisela Mautner share-based compensation is derived from 600,000 share options that vested during the period. Gisela Mautner resigned 12 November 2025 and 1,200,000 options expired, no expense is recorded for the options that expired during the period. 9 James Bonnar share-based compensation is derived from 3,200,000 share options granted during the prior period. 1,000,000 options vest on the first and second anniversary of the grant date (11 June 2025), with the remaining 1,200,000 options vesting in monthly tranches of 100,000 from 11 July 2027 to 11 July 2028, subject to continuous employment.
RkJQdWJsaXNoZXIy MjE2NDg3